China High Purity Medroxyprogesterone Acetate CAS 71-58-9//Penicillin CAS 69-57-8//Penicillin V Potassium Salt CAS 132-98-9//CAS 77883-43-3 Doxazosin Mesylate, Find details about China CAS 77883-43-3, Doxazosin Mesylate from High Purity Medroxyprogesterone Acetate CAS 71-58-9//Penicillin CAS 69-57-8//Penicillin V Potassium Salt CAS 132-98-9//CAS 77883-43-3 Doxazosin Mesylate
Introduction
Name | Doxazosin mesylate |
CAS | 77883-43-3 |
MF | C24H29N5O8S |
MW | 547.58 |
MP | 275-277°C |
Storage temp | Desiccate at RT |
Assay | 99% Min. |
Appearance | White Crystalline Powder |
construction |
Function
Doxazosin mesylate is a new generation of quinazolone alpha 1 receptor blocker developed and marketed by Pfizer. It has a long half-life and can expand blood vessels, reduce vascular resistance, and lower blood pressure by blocking alpha 1 receptors. It selectively blocks the a1 adrenergic receptors in the smooth muscle matrix, capsule and bladder neck of the prostate, improves the symptoms of patients with benign prostatic hyperplasia, and has a good effect on dysuria caused by simple prostatic hyperplasia. In 1988, doxazosin was marketed in Denmark as a drug for the treatment of hypertension. In 1995, the US FDA approved it for the treatment of benign prostatic hyperplasia. In September 2002, doxazosin controlled-release tablets were launched in China and listed in the National Chemicalbook for benign prostate. The drug treatment of hyperplasia provides a new option, and it has been clinically recommended by foreign countries as the first-line drug for anti-hypertension and prostate disease. [Pharmacological action] This product is a new type of highly selective α1 receptor blocker, which has a significant effect on lowering blood pressure, and at the same time has a good effect on improving blood lipid metabolism, and can significantly reduce serum triglycerides and total cholesterol; In addition, it selectively blocks the a1 adrenergic receptors of the smooth muscle matrix, capsule and bladder neck of the prostate, improves the symptoms of patients with benign prostatic hyperplasia, and significantly reduces the effect of benign prostatic hyperplasia, especially for dysuria caused by simple prostatic hyperplasia. Effect, its half-life is long.